Studies suggest India has 254mn people with generalised obesity and 351mn with abdominal obesity, a disease burden that makes it one of the most attractive potential markets in the world for weight-loss therapies
Leaky brain in neurological and psychiatric disorders: drivers and consequences
The price can vary widely, depending on insurance coverage, the specific brand, and chosen pharmacy
Yuan Z, Cai S, Yan C, Rao S, Cheng S, Xu F, et al
1 "These initial data shared at The Liver Meeting demonstrated that semaglutide 2.4 mg slowed MASH progression and reversed existing liver damage," said Arun Sanyal, MD, principal investigator of the study, and Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University